Synapse - Igor Odintsov

Results (4)

Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification

Journal Article

Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Journal Article

Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
Nature Cancer (2023)

Fulltext@MSK | Save

Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification

Journal Article

Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

Targeting mTOR and MEK or ERK inhibits the growth of PDX models of NF1-deficient pediatric sarcoma

Meeting Abstract

Lu, Y. C.; Odintsov, I.; Khodos, I.; Mattar, M.; Glade Bender, J.; Wexler, L.; de Stanchina, E.; Ladanyi, M.; Somwar, R.
Pediatric Blood and Cancer (2022)

Fulltext@MSK | Save